Resistance To Anti Cd20 Antibodies And Approaches For Their Reversal
Download Resistance To Anti Cd20 Antibodies And Approaches For Their Reversal full books in PDF, epub, and Kindle. Read online free Resistance To Anti Cd20 Antibodies And Approaches For Their Reversal ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : |
| Publisher | : Elsevier |
| Total Pages | : 444 |
| Release | : 2023-08-30 |
| Genre | : Computers |
| ISBN | : 0443192014 |
Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies. In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book. It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal. • Presentation of current research, critical analyses, in-depth literature reviews, and the latest clinical reports on anti-CD20 antibody treatment• Discussion of recent developments of anti-CD20 antibodies in cancer and noncancer diseases treatment, possible resistance mechanisms and their reversals, as well as the exciting therapeutic opportunities offered by anti-CD20 antibodies in combination with chemotherapy or other treatment modalities• Utilization of a number of diagrams to visually illustrate complex content and plenty of tables to summarize important information
| Author | : |
| Publisher | : Elsevier |
| Total Pages | : 442 |
| Release | : 2023-09-22 |
| Genre | : Computers |
| ISBN | : 0443192006 |
Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies. In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book. It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.
| Author | : Benjamin Bonavida |
| Publisher | : Academic Press |
| Total Pages | : 232 |
| Release | : 2024-07-15 |
| Genre | : Medical |
| ISBN | : 0128167386 |
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. - Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance - Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment - Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
| Author | : Shi Hu |
| Publisher | : Academic Press |
| Total Pages | : 258 |
| Release | : 2022-11-11 |
| Genre | : Science |
| ISBN | : 0128215852 |
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists.Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance. - Presents detailed descriptions on the history, chemistry, mechanism of action, structure-function relationships, pharmacology, side effects, dosing and formulation of new sensitizers to anti-EGFR antibodies - Provides molecular structures for all novel anticancer drugs, along with strategies to overcome resistance to anti-EGFR antibodies - Encompasses up-to-date information on the cancer drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in emerging areas of precision medicine
| Author | : Sheykhhasan, Mohsen |
| Publisher | : IGI Global |
| Total Pages | : 640 |
| Release | : 2024-08-28 |
| Genre | : Medical |
| ISBN | : |
Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment.
| Author | : Mengyuan Dong |
| Publisher | : OAE Publishing Inc. |
| Total Pages | : 11 |
| Release | : 2024-02-19 |
| Genre | : Medical |
| ISBN | : |
Aim: The purpose of this study is to enhance the understanding of bladder cancer and the role of cancer-associated fibroblasts (CAFs) in its progression. We aim to identify CAF-specific biomarkers and develop a prognostic prediction model based on CAFs, thereby contributing to the advancement of treatment strategies and the identification of prognostic and predictive biomarkers for bladder cancer. Method: We employed single-cell RNA sequencing to detect biomarkers for CAFs in bladder cancer cells. Bladder cancer cohorts were categorized into low- and high-CAF groups using the ssGSEA algorithm. The study also explored the association between CAF-related scores, immune-related cells, and immune checkpoint-related genes. Furthermore, we performed GSVA analysis to understand the biological features of CAFs and their link to various cancer-related pathways. Result: Ten genes were identified as CAF markers in bladder cancer cells. A significant difference was found with 2712 differentially expressed genes between low-CAF and high-CAF tissues. The CAFs-based prognostic prediction model included nine genes (ALDH1L2, AL450384.2, EMP1, LINC02362, WFIKKN1, GOLGA8A, POU5F1, AL354919.2, PTPRR), which are potentially crucial in predicting bladder cancer prognosis. The GSVA analysis revealed the involvement of several cancer-related pathways, such as WNT, toll-like receptor, TGF-beta, MAPK, and MTOR signaling pathways, in the CAFs-based prognostic model. Conclusion: This study highlights the significant role of CAFs in the progression and prognosis of bladder cancer. The identified CAF biomarkers and the constructed prognostic model provide valuable insights for future research and potential therapeutic targets. CAF-dependent pathways are promising for the development of new treatments and improving the prognosis of bladder cancer patients.
| Author | : Benjamin Bonavida |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 431 |
| Release | : 2008-07-31 |
| Genre | : Medical |
| ISBN | : 1597454745 |
This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.
| Author | : Benjamin Bonavida |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 210 |
| Release | : 2013-08-04 |
| Genre | : Medical |
| ISBN | : 1461476542 |
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
| Author | : M. A. Hayat |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 500 |
| Release | : 2010-04-07 |
| Genre | : Medical |
| ISBN | : 9048131863 |
There are more than 100 types of cancers In Part II, head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500,000. These with cancer every year, and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma, salivary gland tumors, tons- the year 2020. In 2005, 7. 6 million peo- lar cancer, tongue cancer, nasopharyngeal ple died of cancer, that is, 13% of the 58 carcinoma, and retinoblastoma, which are million deaths worldwide. It is estimated detailed. In Part III, diagnosis, therapy, and that 9 million people will die from can- prognosis of thyroid carcinoma are d- cer worldwide in 2015 and 11. 4 million cussed. The global number of new cases of will die in 2030. More than 70% of all thyroid cancer is ~141,000, and the number cancer deaths occur in low and middle of worldwide thyroid mortalities is ~35,375. income countries. These statistics underlie The number of new cases of this cancer in the fact that cancer is the deadliest of all the United States is ~33,550. Molecular human diseases. The enormity of the glo- genetics of thyroid cancer, gene expr- bal healthcare costs as a result of cancer sion markers for diagnosis, papillary t- cannot be overemphasized.
| Author | : Peter H. Wiernik |
| Publisher | : Cambridge University Press |
| Total Pages | : 1240 |
| Release | : 2003-06-09 |
| Genre | : Medical |
| ISBN | : 9780521791366 |
In this fourth edition of the classic work on malignant blood cancers, the team of editors and over 100 international leaders in the field provide a comprehensive text on the diagnosis and treatment of all hematologic malignancies, both common and rare. The sixty-two chapters are divided into sections on Chronic Leukemias and Related Disorders, Acute Leukemias, Myeloma and Related Disorders, Lymphomas, and Supportive Care, with a devoted editor for each section. This extensively revised and updated edition reflects the tremendous progress in the science and treatment of hematologic malignancies during the eight years since the third edition in 1995. Revisions and new chapters include coverage of stem cell transplantation, molecular genetics, monoclonal antibodies, and new treatment modalities. The excellent discussions of current therapies for all hematologic neoplasms are more detailed than those in general oncology or hematology texts, making this an essential reference for all hematologists and oncologists.
